BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

BACKGROUND: Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with colorectal cancer (CRC) treated with anti-EGFR therapies. This study investigated the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, T, Ura, T, Shibata, N, Takahari, D, Shitara, K, Nomura, M, Kondo, C, Mizota, A, Utsunomiya, S, Muro, K, Yatabe, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048210/
https://www.ncbi.nlm.nih.gov/pubmed/21285991
http://dx.doi.org/10.1038/bjc.2011.19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048210/
https://www.ncbi.nlm.nih.gov/pubmed/21285991
http://dx.doi.org/10.1038/bjc.2011.19

Ejemplares similares